Patients with Protein-Truncating PKD1 Mutations and Mild ADPKD.
暂无分享,去创建一个
A. Paterson | Y. Pei | N. He | M. Lanktree | Xuewen Song | K. Khalili | Pedram Akbari | M. Pourafkari | I. Iliuta | E. Guiard | A. Haghighi | S. Ahmed | Ioan-Andrei Iliuta
[1] T. Weimbs,et al. Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease. , 2019, Cell metabolism.
[2] A. Paterson,et al. Intrafamilial Variability of ADPKD , 2019, Kidney International Reports.
[3] P. McFarlane,et al. Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease , 2018, Canadian journal of kidney health and disease.
[4] M. Patterson,et al. The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] Alexander E. Lopez,et al. A Protein‐Truncating HSD17B13 Variant and Protection from Chronic Liver Disease , 2018, The New England journal of medicine.
[6] D. Landsittel,et al. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. , 2017, Kidney international.
[7] R. Gansevoort,et al. Tolvaptan in Later‐Stage Autosomal Dominant Polycystic Kidney Disease , 2017, The New England journal of medicine.
[8] Vicente E. Torres,et al. Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease , 2017, Kidney international reports.
[9] S. Lynch,et al. The Human Intestinal Microbiome in Health and Disease. , 2016, The New England journal of medicine.
[10] Kaleab Z. Abebe,et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[11] Marie E. Edwards,et al. Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. , 2016, American journal of human genetics.
[12] A. Paterson,et al. Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.
[13] V. Torres,et al. Food Restriction Ameliorates the Development of Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.
[14] R. Salomon,et al. Comprehensive PKD1 and PKD2 Mutation Analysis in Prenatal Autosomal Dominant Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.
[15] Wim Van Biesen,et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] Kaleab Z. Abebe,et al. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.
[17] Eric J. Topol,et al. Protective alleles and modifier variants in human health and disease , 2015, Nature Reviews Genetics.
[18] Chad A Shaw,et al. Somatic mosaicism: implications for disease and transmission genetics. , 2015, Trends in genetics : TIG.
[19] G. Walz,et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management , 2015, The Lancet.
[20] M. Haider,et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. , 2015, Journal of the American Society of Nephrology : JASN.
[21] S. Hazen,et al. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. , 2015, Annual review of medicine.
[22] C. Wanner,et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] V. Torres,et al. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. , 2014, The Journal of clinical investigation.
[24] G. Pazour,et al. Loss of cilia suppresses cyst growth in genetic models of autosomal dominant polycystic kidney disease , 2013, Nature Genetics.
[25] C. Férec,et al. Type of PKD1 mutation influences renal outcome in ADPKD. , 2013, Journal of the American Society of Nephrology : JASN.
[26] Eiji Higashihara,et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.
[27] B. Eckloff,et al. Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. , 2012, Journal of the American Society of Nephrology : JASN.
[28] Zheng Lan,et al. A missense mutation in PKD1 attenuates the severity of renal disease. , 2012, Kidney international.
[29] J. Jonsson,et al. Mutations in multiple PKD genes may explain early and severe polycystic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.
[30] A. Paterson,et al. Genetic variation of DKK3 may modify renal disease severity in ADPKD. , 2010, Journal of the American Society of Nephrology : JASN.
[31] A. Paterson,et al. Family history of renal disease severity predicts the mutated gene in ADPKD. , 2009, Journal of the American Society of Nephrology : JASN.
[32] V. Torres,et al. Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease. , 2009, Kidney international.
[33] K. Bae,et al. Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. , 2008, Kidney international.
[34] F. Cosio,et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.
[35] G. Brosnahan,et al. Volume progression in polycystic kidney disease. , 2006, The New England journal of medicine.
[36] Jonathan C. Cohen,et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.
[37] Ann M. Johnson,et al. Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.
[38] Alexander Pertsemlidis,et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.
[39] M. Breuning,et al. Autosomal dominant polycystic kidney disease: modification of disease progression , 2001, The Lancet.
[40] A. Paterson,et al. Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease. , 2001, American journal of human genetics.
[41] E. Coto,et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2 , 1999, The Lancet.
[42] Bradley J Erickson,et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. , 2015, Journal of the American Society of Nephrology : JASN.
[43] J. Stockman,et al. A New Equation to Estimate Glomerular Filtration Rate , 2011 .